This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Martha D. McDaniel, MD; W. Thomas Huntsman, MD; Thomas O'C. Miett, MD; Jack L. Cronenwett, MD

Arch Surg. 1987;122(8):887-892.

Abstract
• This study examined the effect of selective thromboxane synthase inhibition and nonselective cyclooxygenase inhibition on vascular graft patency and indium 111–labeled platelet deposition in 35 mongrel dogs undergoing carotid artery replacement with 4 mm x 4 cm polytetrafluoroethylene (PTFE) (one side) and Dacron (opposite side) end-to-end grafts. Aspirin-dipyridamole therapy improved one-week graft patency, from 46% in untreated dogs to 93% in treated dogs. Thromboxane synthase inhibition (U-63557A) improved graft patency in these dogs to 81%. Both drug treatments reduced platelet deposition on Dacron and PTFE grafts by 48% to 68% compared with control dogs. Dacron grafts accumulated significantly more platelets than PTFE grafts but had comparable patency rates. Low-dose aspirin therapy had no significant effect on either graft patency or platelet deposition. All treatment groups showed a 60% to 76% reduction in serum thromboxane B₂, but only thromboxane synthase inhibitor treatment increased plasma 6-keto-prostaglandin F₁ by 100%. Selective thromboxane synthase inhibition improved small-caliber prosthetic graft patency to the same extent as did conventional cyclooxygenase inhibition in this preliminary study.

(Arch Surg 1987;122:887-892)

Author Affiliations
From the Section of Vascular Surgery, Dartmouth-Hitchcock Medical Center, Hanover, NH.

Footnotes
Accepted for publication May 26, 1987.

Read before the 13th Annual Meeting of the New England Society for Vascular Surgery, Dixville Notch, NH, Sept 25, 1986.

Reprint requests to Section of Vascular Surgery, Dartmouth-Hitchcock Medical Center, Hanover, NH 03756 (Dr McDaniel).